What the half-life means in plain terms
Half-life is the time it takes for the concentration of a drug in the blood to fall by half. For retatrutide, that is approximately 6 days. This matters because it tells you how often the drug needs to be injected to keep enough of it in the body — in this case, once a week. It also tells you that after stopping, the drug stays in the body for about 30–36 days before it reaches near-undetectable levels (roughly 5–6 half-lives).
The 6-day half-life was measured in the first-in-human Phase 1b study in adults with type 2 diabetes. It is what drives the once-weekly injection schedule used in all retatrutide trials to date.
The extended half-life is not a natural property of the retatrutide peptide itself — it is engineered by a chemical modification that makes the drug cling to albumin, the main carrier protein in blood, which acts as a slow-release reservoir. Without that modification, the peptide would clear in hours. This engineering is also what keeps the retatrutide half life study results consistent across dose groups in Phase 1b.
Phase 1b pharmacokinetics data
The first-in-human Phase 1b pharmacokinetic study (Urva et al., Lancet, 2022) enrolled 72 adults with type 2 diabetes and HbA1c 7.0–10.5%. Dose groups received once-weekly subcutaneous retatrutide at 0.5 mg, 1.5 mg, 3 mg, 3/6 mg, and 3/6/9/12 mg (multi-ascending doses within a group) over 12 weeks [4].
Key pharmacokinetic findings:
- Half-life: ~6 days. Consistent across dose groups; supports once-weekly dosing with stable trough-to-peak plasma concentration ratios.
- Absorption route: subcutaneous. All doses were injected into subcutaneous adipose tissue (fat layer under skin). No IV or oral formulation was studied.
- Weight loss (pharmacodynamic endpoint): −8.96 kg placebo-adjusted at the highest dose group over 12 weeks (90% CI: −11.16 to −6.75 kg) [4].
- Daily glucose reduction: −2.8 mmol/L at 3 mg.
- Treatment-emergent adverse events: 63%, predominantly GI. Acceptable safety profile.
The Phase 1b study was preceded by NCT04143802, Eli Lilly's Phase 1 single/multiple ascending-dose study in healthy participants establishing initial safety and PK [7].
Structural basis of extended half-life
Retatrutide is a 39-amino-acid synthetic peptide built on a GIP-based backbone. Its molecular formula is C221H342N46O68 (free acid), molecular weight approximately 4731.33 Da. The extended plasma half-life is engineered by a C20 fatty-diacid acyl chain attached to the peptide [3].
Fatty-acid acylation is the same engineering strategy used to extend the half-lives of other GLP-1-class compounds. The C20 chain binds non-covalently to albumin (the most abundant protein in plasma), which:
- Acts as a slow-release depot, releasing free retatrutide gradually
- Dramatically reduces renal clearance (kidneys cannot filter the large albumin-bound complex)
- Protects the peptide from peptidase degradation
The binding affinity at GIPR is approximately 8.9× that of native GIP; at GCGR and GLP-1R it is 0.3× and 0.4× native hormones respectively — potency that was specifically tuned during the drug's design to balance receptor arms [3].
The cryo-EM structural study (Li et al., Cell Discovery, 2024) resolved how retatrutide engages all three receptor complexes. At GLP-1R and GCGR, the peptide's N-terminal ECL1 (extracellular loop 1) adopts a rigid alpha-helix; at GIPR it adopts a flexible loop. The structural flexibility at GIPR is believed to contribute to its higher relative GIPR potency [3].
Pharmacokinetics and once-weekly dosing rationale
The ~6-day half-life means plasma concentration peaks within approximately 24 hours post-injection, then declines to a trough level over the next 6 days. By injection day 7, concentration is approximately 50% of the peak. The trough concentration is still well within the receptor-active range — this is why steady-state drug exposure is maintained with once-weekly injections without wide peak-to-trough swings.
By comparison, the first generation of GLP-1 agonists had half-lives of hours (liraglutide: ~13 hours, requiring once-daily dosing). Longer-acting compounds in the class — engineered with similar fatty-acid albumin-binding chemistry — achieve weekly dosing.
The 2025 pipeline review (Madsbad et al., Expert Opinion on Investigational Drugs) discussed PK/PD profiles of GLP-1 mono-, dual-, and triple-agonists, identifying the pharmacokinetic class principle: extended half-life via fatty-acid acylation enables once-weekly dosing and smooths out peak-related GI side effects compared with shorter-acting agents [12].
For context on what the drug does at the receptors the PK delivers it to, see how does retatrutide work.
Gray-market material and PK uncertainty
The approximately 6-day half-life was measured in pharmaceutical-grade investigational product of verified identity, potency, and sterility, administered under clinical trial conditions. These figures do not apply to gray-market research-labeled material, which has no verified identity or concentration.
If the material does not contain authentic retatrutide at the labeled concentration — which independent analyses of similar gray-market peptides have found to be a real risk — the pharmacokinetics would be entirely different. There is no validated storage, reconstitution, or handling specification for non-trial retatrutide. These are not abstract warnings — they are the direct consequences of the compound's investigational status.